Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.
about
Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxA hybrid multistage protein vaccine induces protective immunity against murine malariaPhase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectorsA viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activityTransgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1Novel viral vectored vaccines for the prevention of influenza.Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain.Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route.The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody.Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposureT cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirusPhase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum.Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference.Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates.A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria VaccineRecombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.Covalent decoration of adenovirus vector capsids with the carbohydrate epitope αGal does not improve vector immunogenicity, but allows to study the in vivo fate of adenovirus immunocomplexesEnhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens.Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technologyTailoring a Combination Preerythrocytic Malaria VaccineThe utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment.A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances Chlamydia trachomatis Clearance.Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines.A chimeric protein-based malaria vaccine candidate induces robust T cell responses against Plasmodium vivax MSP119.Assessment of antibody-dependent respiratory burst activity from mouse neutrophils on Plasmodium yoelii malaria challenge outcome.Synergism/complementarity of recombinant adenoviral vectors and other vaccination platforms during induction of protective immunity against malaria.Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets.Recombinant modified vaccinia virus Ankara-based malaria vaccines.A polyvalent hybrid protein elicits antibodies against the diverse allelic types of block 2 in Plasmodium falciparum merozoite surface protein 1.A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers.Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge.A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.Heterologous prime-boost immunization regimens using adenovirus vector and virus-like particles induce broadly neutralizing antibodies against H5N1 avian influenza viruses.Developing novel strategies to prevent parasitic infections.
P2860
Q24273364-349C8510-004B-40EB-81DC-7ACC6B3BBE36Q28730779-E2B99AAC-9FFD-4E82-BDD9-82A49575B1DEQ28731894-098E7837-E388-443F-8569-3081C3E62C61Q28740771-9C9031D2-8763-49B4-8D4C-DAFB3A761C3BQ28743564-C7C445A7-02DE-4084-96A5-C135ECE036B4Q30418570-A2606850-CB97-4C52-BD50-18181BA20046Q33779750-AC3C1143-607D-41B2-9028-99C2E3B3F9F9Q34072792-69BA0C7C-33E0-4B67-8014-FBBD660BFE64Q34241973-538BA02B-336A-4AD9-BD36-C596B64D83D5Q34257253-2E758DB1-8DF0-457F-B4BC-DC8AB7F84C58Q34416263-CDDBDC34-74E9-4AE7-8625-5A798C1C0889Q34600955-8FFE97FB-1438-4FE8-B0DC-1EBEFAC9B4DBQ35177864-AB796C69-0A7D-4068-ACFB-E239FD75948EQ35623459-4D5DE472-D6DF-47A2-A5E3-37F6D7E05408Q35718341-A0FB5FB7-59AC-4AF2-A845-92CE4C0373FBQ35741989-DFEF5470-9BE5-4F9D-9B0D-2290C1DBEBD3Q35771456-C9CBE56B-0E20-4935-858F-555B49C20FE4Q35813430-4F3F3C9C-6CD2-4FCD-B05F-A938EBAD3236Q36003208-D2CC56DA-01CC-4F43-8ABC-C7617F8C03F5Q36043731-E851C2F0-4D99-4CA4-935A-57C7DE2CDECEQ36363270-68FEE5D1-B06C-4C43-B518-7944A926FF1EQ36384456-010552E2-9F31-4F04-A96A-D7AB138DF070Q36442817-A2AA533B-5E16-4103-B300-D2EC0E429EE6Q36631331-B5FE1E4C-E35B-4C40-8E3F-36A9FD68E3EEQ36785777-5F368486-87A3-4377-8855-1036D5258940Q36845154-59763A96-B559-4DFC-AAD5-8C468DCB8C78Q37153663-C17802FD-C7D8-4173-B707-F8AFFE1B6F78Q37314756-385452D5-ACCC-4C47-908B-B89157BD2DA5Q37496763-6165AF55-DB28-43D3-9390-F187C1606066Q37924616-5ADAB5F0-51B7-4EB7-9517-FB78EA864FCDQ38096489-B576FB4D-1F82-459B-B62A-1911D740FCBFQ38618898-D5D12D29-4396-4D02-A25D-796A678618AEQ38729151-FD70265E-54BD-49BC-9336-204566D63B77Q39441716-148EBF5D-0A7F-438B-9738-CCDDADD8F274Q40089181-95A32475-1C0B-4DEE-ACDA-AF1250315A44Q40116170-6AC77C34-9A83-469E-8F9F-318584B7D615Q40210139-68FC6C0E-9472-46CD-8C2E-996E0ECE8EF6Q42286975-C3AD1C66-84BD-41E3-B4A6-F54CE5E4B6D1Q47987209-D802CCE9-BC7A-4701-A2AE-EE36B2F15022
P2860
Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Tailoring subunit vaccine immu ...... st Plasmodium falciparum MSP1.
@ast
Tailoring subunit vaccine immu ...... st Plasmodium falciparum MSP1.
@en
type
label
Tailoring subunit vaccine immu ...... st Plasmodium falciparum MSP1.
@ast
Tailoring subunit vaccine immu ...... st Plasmodium falciparum MSP1.
@en
prefLabel
Tailoring subunit vaccine immu ...... st Plasmodium falciparum MSP1.
@ast
Tailoring subunit vaccine immu ...... st Plasmodium falciparum MSP1.
@en
P2860
P50
P921
P1433
P1476
Tailoring subunit vaccine immu ...... st Plasmodium falciparum MSP1.
@en
P2093
Matthew D J Dicks
Simone C de Cassan
P2860
P304
P356
10.1016/J.VACCINE.2010.08.068
P407
P577
2010-10-01T00:00:00Z